Skip to main content
Erschienen in:

29.11.2022 | Originalien

Endometriumkarzinom – ein Update

verfasst von: Dr. Katharina Steger, Ao.Univ.-Prof. Dr. Alain Zeimet

Erschienen in: Gynäkologie in der Praxis | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

In der im Dezember 2020 publizierten neuen ESGO-ESTRO-ESP-Guideline wird die molekulare Charakterisierung als neuer Standard zur Einteilung des Endometriumkarzinoms empfohlen. Diese Gliederung dient nicht nur der Risikostratifizierung, sondern ist auch wegweisend für die prognostische Einschätzung und Therapieentscheidung. Goldstandard der Therapie ist weiterhin ein chirurgisches Vorgehen im Sinne einer laparoskopischen totalen Hysterektomie mit bilateraler Salpingoophorektomie. Die Durchführung eines Sentinel-Lymphknoten-Samplings liefert dabei heute in den meisten Fällen ausreichend Informationen über den Lymphknotenstatus der Patientin und wird somit der vollständigen Lymphknotendissektion vorgezogen. In der Therapie von Patientinnen mit Endometriumkarzinom im fortgeschrittenen Stadium oder mit Rezidiverkrankung eröffnet die Immuntherapie in Form von Checkpointinhibitoren (z. B. Pembrolizumab oder Dostarlimab) als Monotherapie bei Mismatch-repair-defizienten bzw. in der Kombination von Pembrolizumab mit einem Multikinaseinhibitor (z. B. Lenvatinib) bei Mismatch-repair-profizienten Karzinomen neue Möglichkeiten in der Zweitlinientherapie.
Literatur
2.
Zurück zum Zitat Zhang S, Gong TT, Liu FH, Jiang YT, Sun H, Ma XX et al (2019) Global, regional, and national burden of endometrial cancer, 1990–2017: results from the global burden of disease study, 2017. Front Oncol 9:1440CrossRef Zhang S, Gong TT, Liu FH, Jiang YT, Sun H, Ma XX et al (2019) Global, regional, and national burden of endometrial cancer, 1990–2017: results from the global burden of disease study, 2017. Front Oncol 9:1440CrossRef
3.
Zurück zum Zitat Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387(10023):1094–1108CrossRef Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387(10023):1094–1108CrossRef
4.
Zurück zum Zitat Koskas M, Amant F, Mirza MR, Creutzberg CL (2021) Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet 155(Suppl 1):45–60CrossRef Koskas M, Amant F, Mirza MR, Creutzberg CL (2021) Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet 155(Suppl 1):45–60CrossRef
5.
7.
Zurück zum Zitat American College of Obstetricians and Gynecologists (2005) ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 106(2):413–425 American College of Obstetricians and Gynecologists (2005) ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 106(2):413–425
8.
Zurück zum Zitat Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA (2006) Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 19(8):1091–1100CrossRef Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA (2006) Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 19(8):1091–1100CrossRef
9.
Zurück zum Zitat Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123(5):802–813CrossRef Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123(5):802–813CrossRef
10.
Zurück zum Zitat Ali A, Black D, Soslow RA (2007) Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 26(2):115–123CrossRef Ali A, Black D, Soslow RA (2007) Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 26(2):115–123CrossRef
11.
Zurück zum Zitat Köbel M, Nelson GS (2018) Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538–549. J Pathol 245(2):249–250CrossRef Köbel M, Nelson GS (2018) Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538–549. J Pathol 245(2):249–250CrossRef
13.
Zurück zum Zitat Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39CrossRef Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39CrossRef
14.
Zurück zum Zitat Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R et al (2017) Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA 317(12):1224–1233CrossRef Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R et al (2017) Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA 317(12):1224–1233CrossRef
15.
Zurück zum Zitat Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS et al (2012) Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30(7):695–700CrossRef Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS et al (2012) Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30(7):695–700CrossRef
16.
Zurück zum Zitat Kaban A, Topuz S, Erdem B, Sozen H, Numanoğlu C, Salihoğlu Y (2018) Is Omentectomy necessary for non-endometrioid endometrial cancer. Gynecol Obstet Invest 83(5):482–486CrossRef Kaban A, Topuz S, Erdem B, Sozen H, Numanoğlu C, Salihoğlu Y (2018) Is Omentectomy necessary for non-endometrioid endometrial cancer. Gynecol Obstet Invest 83(5):482–486CrossRef
17.
Zurück zum Zitat Dutta SW, Trifiletti DM, Grover S, Boimel P, Showalter TN (2017) Management of elderly patients with early-stage medically inoperable endometrial cancer: systematic review and national cancer database analysis. Brachytherapy 16(3):526–533CrossRef Dutta SW, Trifiletti DM, Grover S, Boimel P, Showalter TN (2017) Management of elderly patients with early-stage medically inoperable endometrial cancer: systematic review and national cancer database analysis. Brachytherapy 16(3):526–533CrossRef
18.
Zurück zum Zitat Burg LC, Hengeveld EM, ’t Hout IJ, Bulten J, Bult P, Zusterzeel PLM (2021) Ultrastaging methods of sentinel lymph nodes in endometrial cancer—a systematic review. Int J Gynecol Cancer 31(5):744–753CrossRef Burg LC, Hengeveld EM, ’t Hout IJ, Bulten J, Bult P, Zusterzeel PLM (2021) Ultrastaging methods of sentinel lymph nodes in endometrial cancer—a systematic review. Int J Gynecol Cancer 31(5):744–753CrossRef
19.
Zurück zum Zitat Bogani G, Mariani A, Paolini B, Ditto A, Raspagliesi F (2019) Low-volume disease in endometrial cancer: the role of micrometastasis and isolated tumor cells. Gynecol Oncol 153(3):670–675CrossRef Bogani G, Mariani A, Paolini B, Ditto A, Raspagliesi F (2019) Low-volume disease in endometrial cancer: the role of micrometastasis and isolated tumor cells. Gynecol Oncol 153(3):670–675CrossRef
20.
Zurück zum Zitat León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A et al (2020) Molecular classification of the PORTEC‑3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 38(29):3388–3397CrossRef León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A et al (2020) Molecular classification of the PORTEC‑3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 38(29):3388–3397CrossRef
21.
Zurück zum Zitat van den Heerik A, Horeweg N, Nout RA, Lutgens L, van der Steen-Banasik EM, Westerveld GH et al (2020) PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 30(12):2002–2007CrossRef van den Heerik A, Horeweg N, Nout RA, Lutgens L, van der Steen-Banasik EM, Westerveld GH et al (2020) PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 30(12):2002–2007CrossRef
22.
Zurück zum Zitat Nasioudis D, Roy AG, Ko EM, Cory L, Giuntoli Ii RL, Haggerty AF et al (2020) Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium. Int J Gynecol Cancer 30(8):1089–1094CrossRef Nasioudis D, Roy AG, Ko EM, Cory L, Giuntoli Ii RL, Haggerty AF et al (2020) Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium. Int J Gynecol Cancer 30(8):1089–1094CrossRef
23.
Zurück zum Zitat Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA et al (2013) L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105(15):1142–1150CrossRef Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA et al (2013) L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105(15):1142–1150CrossRef
24.
Zurück zum Zitat Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS et al (2020) Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209). J Clin Oncol 38(33):3841–3850CrossRef Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS et al (2020) Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209). J Clin Oncol 38(33):3841–3850CrossRef
25.
Zurück zum Zitat Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL et al (2020) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 38(26):2981–2992CrossRef Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL et al (2020) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 38(26):2981–2992CrossRef
26.
Zurück zum Zitat Gu H, Li J, Gu Y, Tu H, Zhou Y, Liu J (2017) Survival impact of ovarian preservation on women with early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 27(1):77–84CrossRef Gu H, Li J, Gu Y, Tu H, Zhou Y, Liu J (2017) Survival impact of ovarian preservation on women with early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 27(1):77–84CrossRef
27.
Zurück zum Zitat Garzon S, Uccella S, Zorzato PC, Bosco M, Franchi MP, Student V et al (2021) Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med 112(1):55–69CrossRef Garzon S, Uccella S, Zorzato PC, Bosco M, Franchi MP, Student V et al (2021) Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med 112(1):55–69CrossRef
Metadaten
Titel
Endometriumkarzinom – ein Update
verfasst von
Dr. Katharina Steger
Ao.Univ.-Prof. Dr. Alain Zeimet
Publikationsdatum
29.11.2022
Verlag
Springer Vienna
Erschienen in
Gynäkologie in der Praxis / Ausgabe 4/2022
Print ISSN: 3005-0758
Elektronische ISSN: 3005-0766
DOI
https://doi.org/10.1007/s41974-022-00245-8